139 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
compared to 29 percent of patients receiving placebo in combination with a 52-week steroid taper regimen. Rinvoq’s safety profile in GCA was generally … consistent with that in approved indications, and no new safety signals were identified.
AbbVie announced positive topline results from the Phase 3b/4
8-K
EX-5.1
ABBV
Abbvie Inc
26 Feb 24
Other Events
5:08pm
health or safety reasons or otherwise (including a pandemic).
This letter speaks only as of its date and is delivered in accordance
8-K
EX-99.1
kcix8de1wtzv
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.2
b0vf75hg
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.1
owuo8adyo68pz e8b
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
9ybq7rbj
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
0iorc hn4xl5i3m3rlg
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
rbs5udjytv0hzb
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
PX14A6G
vlm6fti
4 May 23
Letter to shareholders
8:08am
8-K
EX-99.1
h7iivz1341vq yqnsb
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
0dscnj9ugqy64162e8m
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-3.1
9ib4yqzs6
14 Oct 22
Departure of Directors or Certain Officers
5:02pm